The drug formulation study offers promise for treating different respiratory tract infections using a single antimicrobial agent, a paper reports.
List view / Grid view
The Novo Nordisk Foundation is investing up to $260 million in a vaccines research and development initiative focused on respiratory diseases.
Strong influenza and COVID-19 immunogenicity compared to approved standalone vaccines has been demonstrated in Moderna’s combination vaccine, interim Phase I/II trial data shows.
Xofluza® offers the first novel mechanism of action for an influenza antiviral to be approved by the European Commission in almost 20 years.
Moderna is to build an mRNA vaccine manufacturing centre in the UK after finalising a ten-year agreement with the UK government.
Alexandre Le Vert, CEO and Co-Founder of Osivax, explores some evolving approaches to vaccine development that aim to counter the effects of virus mutation.
New agreement reserves million doses of GSK’s pandemic influenza vaccine Adjupanrix to support Europe’s pandemic preparedness.
The research collaboration will enable the sharing of technical skills and materials to expedite Afrigen’s goal of mRNA vaccine production.
Moderna to establish a UK mRNA Innovation and Technology Centre to produce mRNA vaccines for COVID-19, influenza, respiratory syncytial virus (RSV) and more.
Dr Owen Seddon, Consultant in Infectious Diseases and Medical Microbiology at University Hospital of Wales, explains how successes in the development of the coronavirus vaccine must be used in the fight against other vaccine preventable disease.
The results of a recent international study suggest that left-handed gold nanoparticles can increase vaccine effectiveness by 25 percent, providing useful adjuvant capabilities.
The Phase IIa influenza-challenge study will enrol 123 healthy adults and support the development of INNA-051 as a pan-antiviral nasal spray.